Celyad’s off-the-shelf CAR-T data in colorectal cancer early, but serious toxicities haven’t appeared
Several patients in the trial of CYAD-101 combined with chemotherapy responded to treatment, but both a company executive and a gastrointestinal cancer expert cautioned the data were too preliminary to draw conclusions.
